hsa-mir-361: Hsa-mir-361 is a specific microRNA (miRNA) that has been studied in various contexts. It has been included in cDNA synthesis and reverse transcription reactions using the TaqMan® MicroRNA Reverse Transcription Kit and specific RT primers [PMC7998231]. In paired tumor and normal samples, hsa-mir-361 showed lower absolute log fold change (LFC) compared to hsa-miR-16-5p [PMC8186776]. Hsa-mir-361 has not been extensively investigated in the context of common miRNAs, and further research is needed to determine its pan-cancer prognostic potential [PMC6602415]. It has been found to be upregulated in the third trimester of pregnancy, along with other miRNAs such as hsa-miR-let7e, hsa-miR-107, and hsa-miR-370 [PMC9700700]. In the first trimester of pregnancy, hsa-mir-361 was significantly upregulated in patients with gestational diabetes mellitus (GDM) [PMC9700700]. Hsa-mir-361 has also been implicated in various cancer types, including intestinal type T1N0M0 and T1N1M0 tumors [PMC4496000]. Additionally, it has been shown to play a role in cell fusion capacity enhancement and disease progression prediction [PMC4325962] [PMC8706837]. In breast cancer studies, hsa-mir-361 expression was found to be downregulated in docetaxel-resistant cells but upregulated in metastatic tumors. It also targets FGFR1 and MMP-1 genes involved in glycolysis inhibition and invasion inhibition [PMC6208346]. Furthermore, it regulates genes involved in the VEGF signaling pathway as well as genes involved in the TGF-beta signaling pathway [PMC7955132].